Clinical trial NCT00294359 (phase 2/phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: mitomycin c; capecitabine; bevacizumab
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological diagnosis of colorectal cancer

          -  Metastatic disease that is not resectable

          -  Age > 18 years

          -  Any patient in whom the investigator considers capecitabine monotherapy appropriate

          -  Measurable and/or non-measurable disease as assessed by CT scan

          -  ECOG performance status 0, 1 or 2. Patients with PS2 should have serum albumin >30 g/L

          -  No prior chemotherapy except for adjuvant chemotherapy given in association with (i)
             complete resection of primary colon or rectal cancer provided there is no clinical,
             radiological or biochemical evidence of relapse for at least 6 months after completion
             of adjuvant treatment and/or (ii) complete resection of limited colorectal metastases
             to liver and/or lung provided there is no clinical, radiological or biochemical
             evidence of relapse for at least 6 months after completion of adjuvant treatment

          -  Adequate bone marrow function with platelets > 100 X 109/l; neutrophils > 1.5 X 109/l
             i) Adequate renal function, with calculated creatinine clearance >30 ml/min (Cockcroft
             and Gault). For patients with creatinine clearance <50 ml/min the starting dose of
             capecitabine may not be greater than 2000 mg/m2/d (see Section 7.1)

          -  Adequate hepatic function with serum total bilirubin < 1.5 X upper limit of normal
             range

          -  Life expectancy of at least 12 weeks

          -  No other concurrent uncontrolled medical conditions

          -  No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ
             of the uterine cervix or any other cancer treated with curative intent >2 years
             previously without evidence of relapse

          -  Women and partners of women of childbearing potential must agree to use adequate
             contraception

          -  Written informed consent

        Exclusion Criteria:

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent or to complete the protocol

          -  Patients with a lack of physical integrity of the upper gastrointestinal tract, or
             known malabsorption syndromes.

          -  Uncontrolled hypertension

          -  Active bleeding disorders within the last 3 months

          -  Patients on full anticoagulation with warfarin. (Patients who require full
             anticoagulation and who wish to participate in the study should be converted to low
             molecular weight heparin). (Note: patients receiving full anticoagulation with low
             molecular weight heparin should have no evidence of tumour invading or abutting major
             blood vessels on any prior CT scan)

          -  Participation in any investigational drug study within the previous 8 weeks

          -  Patients with uncontrolled clinically significant cardiac disease, arrhythmias or
             angina pectoris

          -  Patients with a history of acute myocardial infarction or cerebrovascular accident
             within the last 12 months

          -  Regular use of aspirin (>325mg/day) or NSAIDs (low dose aspirin (<325 mg/d), or
             occasional use of NSAIDs is acceptable)

          -  CNS metastases

          -  Major surgical procedure within the last 28 days

          -  Serious non-healing wound, ulcer or bone fracture

          -  24 hour urinary protein > 2g/ 24 hours ( performed if urine dipstick > 1+ )

          -  Pregnancy or lactation